Search research articles
Contact Us
Filters
Showing results (231-240 of 263) with videos related to
Page
of 27
Sort By:
Nature Biotechnology
|
January 7, 2022
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors
Christopher W Davies, Angela J Oh, Rana Mroue, et al.
Histopathology
|
June 3, 2024
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage
Jane K Nguyen, Lara R Harik, Eric A Klein, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
February 11, 2022
Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma
Emily Chan, Jesse K McKenney, Sarah Hawley, et al.
Histopathology
|
March 29, 2022
Granulomas associated with renal neoplasms: A multi-institutional clinicopathological study of 111 cases
Ankur R Sangoi, Fiona Maclean, Sambit Mohanty, et al.
Journal of Medicinal Chemistry
|
March 12, 2016
Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study
Robert Heald, Krista K Bowman, Marian C Bryan, et al.
Journal of Medicinal Chemistry
|
October 13, 2015
Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study
Robert Heald, Krista K Bowman, Marian C Bryan, et al.
Cancer Research
|
November 9, 2022
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Jonathan Chou, Emily A Egusa, Sinan Wang, et al.
Nature Communications
|
November 10, 2022
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Jennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.
The Lancet. Oncology
|
February 23, 2017
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
Van K Morris, Mohamed E Salem, Halla Nimeiri, et al.
Nature Communications
|
September 10, 2025
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
Kevin Chang, Henry M Delavan, Elizabeth Yip, et al.
Page
of 27
Search research articles
Search
Showing results (231-240 of 263) with videos related to
Sort By:
Page
of 27
Nature Biotechnology
|
January 7, 2022
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors
Christopher W Davies, Angela J Oh, Rana Mroue, et al.
Histopathology
|
June 3, 2024
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage
Jane K Nguyen, Lara R Harik, Eric A Klein, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
February 11, 2022
Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma
Emily Chan, Jesse K McKenney, Sarah Hawley, et al.
Histopathology
|
March 29, 2022
Granulomas associated with renal neoplasms: A multi-institutional clinicopathological study of 111 cases
Ankur R Sangoi, Fiona Maclean, Sambit Mohanty, et al.
Journal of Medicinal Chemistry
|
March 12, 2016
Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study
Robert Heald, Krista K Bowman, Marian C Bryan, et al.
Journal of Medicinal Chemistry
|
October 13, 2015
Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study
Robert Heald, Krista K Bowman, Marian C Bryan, et al.
Cancer Research
|
November 9, 2022
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Jonathan Chou, Emily A Egusa, Sinan Wang, et al.
Nature Communications
|
November 10, 2022
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Jennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.
The Lancet. Oncology
|
February 23, 2017
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
Van K Morris, Mohamed E Salem, Halla Nimeiri, et al.
Nature Communications
|
September 10, 2025
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
Kevin Chang, Henry M Delavan, Elizabeth Yip, et al.
Page
of 27